Navigation Links
Mylan Announces Appointment of M. Fabiana Lacerca as Senior Vice President and Chief Compliance Officer
Date:9/14/2007

PITTSBURGH, Sept. 14 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) today announced the appointment of M. Fabiana Lacerca to the position of Senior Vice President and Chief Compliance Officer.

Ms. Lacerca joins Mylan from Bristol-Meyers Squibb where she was Director of Compliance for Latin America, Canada and Puerto Rico. While there, she was responsible for all compliance-related matters in those regions. Prior to Bristol-Meyers Squibb, Ms. Lacerca held executive and senior counsel positions with Merck & Co., Microsoft and AT&T.

Ms. Lacerca has extensive experience in the areas of multi-jurisdictional corporate compliance, international business transactions, pharmaceutical industry regulation, corporate policy and international environmental law and has advised on opportunities and legal trends within the government as well as corporate sectors.

Mylan Vice Chairman and CEO Robert J. Coury commented: "As we transition to becoming a global leader in our industry we are committed to maintaining a culture of integrity and quality across all lines of our business. It is with great pleasure, therefore, to welcome Fabiana to Mylan. Fabiana has tremendous experience and an exemplary track record in international corporate compliance, which she has gained advising a number of Fortune 100 companies on a wide range of issues, including corporate policy and cross border transactions. Fabiana's extensive experience counseling companies in the pharmaceutical industry with operations in multiple countries will be invaluable to Mylan's operations around the world."

Ms. Lacerca earned a master's of law (LL.M) from UCLA; a specialization in international environmental law from the Universidad de Buenos Aires; and a bachelor's of law from the Universidad de Buenos Aires.

Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc., and a controlling interest in Matrix Laboratories Limited, India. Mylan develops, licenses, manufactures, markets and distributes an extensive line of generic and proprietary products. For more information about Mylan, please visit http://www.mylan.com.


'/>"/>
SOURCE Mylan Laboratories Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Wins Its Amlodipine Case With Pfizer
2. Mylan Announces Tentative FDA Approval for Its ANDA
3. Mylan Announces Final FDA Approval for Fluoxetine Capsules
4. PM announces a new health care order for India
5. Ramdoss Announces Introduction of RCH-II
6. Britain Announces Third Transfusion Related Mad Cow Case
7. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
8. Tibet Announces the Dalai Lama’s Tour of South Americ
9. NHS announces further Cost cutting Measures
10. Indian PM Announces Of Setting Up India Study Center At Tashkent
11. PowderMed Announces Needle-Less Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... ... could substantially improve drug safety and minimize the cost of development. In this ... channel inhibition using cell lines and for cardiac toxicity using induced pluripotent stem ...
(Date:4/28/2017)... , ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... name the Creator responds to and which He does not. Yisrayl says with so ... one is the true name, but he says with a little Scripture, backed with a ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... their work assisting the Brooke Grove Foundation implement a Microsoft Dynamics GP solution ... Solutions, a leading ERP expert that specializes in long-term care, Brooke Grove now ...
(Date:4/28/2017)... ... April 28, 2017 , ... Rob Lowe is a popular actor that has ... presence to an educational purpose as the host of the “Informed” series. The program ... a recent episode, the series focuses on thyroid cancer. , Although thyroid cancer is ...
(Date:4/27/2017)... and DENVER (PRWEB) , ... April 27, 2017 ... ... Health, the nation’s leading respiratory hospital, based in Denver, Colorado, announced an agreement ... is enabled by the continuing support of the Jane and Leonard Korman Family ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Research and ... Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 Mn ... by 2024, expanding at a CAGR of 5.6% from 2016 ...
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
(Date:4/19/2017)... April 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) ... & Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... , Chief Executive Officer of the Company is scheduled to present ... Richard Bear and the Chairman of the Board, Tony ... ...
Breaking Medicine Technology: